U.S. markets open in 17 minutes
  • S&P Futures

    3,660.25
    +6.00 (+0.16%)
     
  • Dow Futures

    29,299.00
    +14.00 (+0.05%)
     
  • Nasdaq Futures

    11,238.00
    +9.75 (+0.09%)
     
  • Russell 2000 Futures

    1,685.20
    +3.10 (+0.18%)
     
  • Crude Oil

    80.63
    -0.60 (-0.74%)
     
  • Gold

    1,673.40
    +4.80 (+0.29%)
     
  • Silver

    18.92
    +0.21 (+1.14%)
     
  • EUR/USD

    0.9758
    -0.0061 (-0.62%)
     
  • 10-Yr Bond

    3.7120
    -0.0350 (-0.93%)
     
  • Vix

    31.41
    +1.23 (+4.08%)
     
  • GBP/USD

    1.1059
    -0.0064 (-0.57%)
     
  • USD/JPY

    144.5550
    +0.1120 (+0.08%)
     
  • BTC-USD

    19,279.51
    +16.93 (+0.09%)
     
  • CMC Crypto 200

    440.94
    -5.04 (-1.13%)
     
  • FTSE 100

    6,883.09
    +1.50 (+0.02%)
     
  • Nikkei 225

    25,937.21
    -484.84 (-1.83%)
     

Investors in Thorne HealthTech (NASDAQ:THRN) have unfortunately lost 34% over the last year

·3 min read

Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. When you buy individual stocks, you can make higher profits, but you also face the risk of under-performance. Unfortunately the Thorne HealthTech, Inc. (NASDAQ:THRN) share price slid 34% over twelve months. That's well below the market decline of 20%. Because Thorne HealthTech hasn't been listed for many years, the market is still learning about how the business performs. The last week also saw the share price slip down another 6.6%. However, this move may have been influenced by the broader market, which fell 4.5% in that time.

Since shareholders are down over the longer term, lets look at the underlying fundamentals over the that time and see if they've been consistent with returns.

See our latest analysis for Thorne HealthTech

There is no denying that markets are sometimes efficient, but prices do not always reflect underlying business performance. One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price.

Thorne HealthTech managed to increase earnings per share from a loss to a profit, over the last 12 months.

Earnings per share growth rates aren't particularly useful for comparing with the share price, when a company has moved from loss to profit. But we may find different metrics more enlightening.

Thorne HealthTech managed to grow revenue over the last year, which is usually a real positive. Since we can't easily explain the share price movement based on these metrics, it might be worth considering how market sentiment has changed towards the stock.

The image below shows how earnings and revenue have tracked over time (if you click on the image you can see greater detail).

earnings-and-revenue-growth
earnings-and-revenue-growth

We know that Thorne HealthTech has improved its bottom line lately, but what does the future have in store? If you are thinking of buying or selling Thorne HealthTech stock, you should check out this free report showing analyst profit forecasts.

A Different Perspective

Thorne HealthTech shareholders are down 34% for the year, even worse than the market loss of 20%. That's disappointing, but it's worth keeping in mind that the market-wide selling wouldn't have helped. With the stock down 5.9% over the last three months, the market doesn't seem to believe that the company has solved all its problems. Given the relatively short history of this stock, we'd remain pretty wary until we see some strong business performance. Before spending more time on Thorne HealthTech it might be wise to click here to see if insiders have been buying or selling shares.

For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here